Su Yinghan, Su Changqing, Qin Lunxiu
Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute, Fudan University, Shanghai 200040, China; Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.
National Center for Liver Cancer (NCLC), Eastern Hepatobiliary Surgery Hospital, Navy Military Medical University, Shanghai 200438, China.
Transl Oncol. 2022 Nov;25:101530. doi: 10.1016/j.tranon.2022.101530. Epub 2022 Sep 9.
Oncolytic virotherapy has become an important strategy in cancer immunotherapy. Oncolytic virus (OV) can reshape the tumor microenvironment (TME) through its replication-mediated oncolysis and transgene-produced anticancer effect, inducing an antitumor immune response and creating favorable conditions for the combination of other therapeutic measures. Extensive preclinical and clinical data have suggested that OV-based combination therapy has definite efficacy and promising prospects. Recently, several clinical trials of oncolytic virotherapy combined with immunotherapy have made breakthroughs. This review comprehensively elaborates the OV types and their targeting mechanisms, the selection of anticancer genes armed in OVs, and the therapeutic modes of action and strategies of OVs to provide a theoretical basis for the better design and construction of OVs and the optimization of OV-based therapeutic strategies.
溶瘤病毒疗法已成为癌症免疫治疗中的一项重要策略。溶瘤病毒（OV）可通过其复制介导的溶瘤作用和转基因产生的抗癌效应重塑肿瘤微环境（TME），诱导抗肿瘤免疫反应，并为其他治疗措施的联合创造有利条件。大量的临床前和临床数据表明，基于OV的联合疗法具有确切疗效和广阔前景。最近，几项溶瘤病毒疗法联合免疫疗法的临床试验取得了突破。本综述全面阐述了OV的类型及其靶向机制、OV中携带的抗癌基因的选择，以及OV的治疗作用模式和策略，为更好地设计和构建OV以及优化基于OV的治疗策略提供理论依据。
